Form 4: Allogene Therapeutics Director Vicki Sato Reports Acquisition and Disposal of Shares
SEC Form 4
Director Vicki Sato reports acquiring and disposing of Allogene Therapeutics shares and stock options on June 5, 2024.
Summary
- On June 5, 2024, Vicki Sato, a director of Allogene Therapeutics, Inc., reported acquiring 61,475 shares of common stock at $0 and disposing of 61,475 shares.
- Following these transactions, Sato directly owns 162,575 shares of Allogene Therapeutics common stock.
- Sato also acquired 95,541 stock options with an exercise price of $2.44, exercisable starting June 5, 2024, and expiring on June 5, 2034.
- These options vest in 12 equal monthly installments.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document is a standard SEC filing reporting transactions by a company director. The acquisition of stock options could be seen as a slightly positive sign.
Positives
- The acquisition of stock options could be seen as a positive sign of confidence in the company's future performance by a director.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.
Stakeholder Impact
- The transactions reported may influence investor perception of Allogene Therapeutics.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: acquisition and disposal of common stock and acquisition of stock options. |
| 06/05/2034 | Expiration date of the acquired stock options. |
| 06/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.